The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash ...

The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently ...

Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, environmental, and genetic ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

悉尼 - 澳大利亚生物技术公司Kazia Therapeutics Limited (NASDAQ: KZIA)已确定将于2024年12月与美国食品和药物管理局(FDA)举行C类会议,讨论其脑癌药物paxalisib在治疗胶质母细胞瘤(GBM)方面的注册途径。 该公司的主要候选药物paxalisib旨在穿透血脑屏障并抑制PI3K/mTOR通路,这是肿瘤学中的一个关键靶点。该药物已获得FDA授予的孤 ...

A new research paper titled "Initiation of tumor dormancy by the lymphovascular embolus" has been published in Oncotarget ...